Cis-Diaminodichloroplatinum (II) Chemotherapy for Advanced Adenocarcinoma of the Upper Gastrointestinal Tract
- 1 January 1985
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 42 (2) , 69-71
- https://doi.org/10.1159/000226003
Abstract
A phase II study of cis-diaminodichloroplatinum (II) (cis-DDP) was carried out in 55 patients with advanced adenocarcinoma of the upper gastrointestinal tract. The drug was given at a dose of 100 mg/m2 i.v. over 2 h every 3–4 weeks, with hydration and mannitol diuresis. There were 3 partial responses (6%) among 51 evaluable patients (esophagus 12, stomach 16, pancreas 14, liver 6, and biliary 3). Toxicity was moderate with cumulative nephrotoxicity being the most serious side effect. Myelosuppression was noted in 25% of patients, all having had prior therapy with mitomycin C and nitrosoureas. Activity of cis-DDP as a single agent against adenocarcinoma of the upper gastrointestinal tract in our patient population was minimal.Keywords
This publication has 1 reference indexed in Scilit:
- Cis-diamminedichloroplatinum (II)Annals of Internal Medicine, 1977